Effect (mean ± SEM) of iPTH treatment on peripheral blood cell expansion. (A-F) After primary competitive repopulation. (H) After secondary competitive repopulation. (A-F) Percentage of CD45.2⁺ myeloid cells (CD11b⁺), granulocytic cells (GR-1⁺), and B lineage cells (B220⁺) in the peripheral blood of untreated WT recipient mice that received CD45.2⁺ BM donor cells mixed in a 1:2 ratio with CD45.1⁺ competitor BM cells. CD45.2⁺ BM cells were obtained from WT, TCRβKO, and reconstituted TCRβKO mice treated with iPTH or vehicle for 4 weeks. CD45.1⁺ BM cells were obtained from untreated WT mice. (G) Relative frequency of donor-derived CD45.2⁺LSK cells in the BM of primary recipients at death. (H) Percentage of donor-derived CD45.2⁺ cells in the peripheral blood of secondary recipients 10 weeks after transplantation. In these experiments, CD45.1/CD45.2 BM cells were obtained from primary recipients at death, mixed in a 1:2 ratio with CD45.1⁺ competitor BM cells from untreated WT mice, and transplanted into CD45.1⁺ untreated WT recipients. n = 10 donor and 10 recipient mice per group *P < .05 compared with the corresponding vehicle-treated group.